Intercytex to raise L12 million in placing
Cambridge, UK-based Intercytex, a cell therapy company focused on esthetic medicine and tissue repair, plans to raise L12.0 million ($24.0 million) in a placing of new ordinary shares to institutional investors in the UK and continental Europe.
The placing is conditional on, inter alia, the approval of shareholders. A circular convening an extraordinary general meeting of the company, which is expected to take place on May 29, is being posted to shareholders today.
The net proceeds of the fundraising will be approximately L11.4 million, which Intercytex intends to use to: launch of its facial rejuvenation product, Vavelta, in the UK; complete the Phase III trial for ICX-PRO and file a Biological License Application; continue the Phase II programs for Vavelta and ICX-TRC (for male pattern baldness); and conduct further trials for ICX-SKN (skin graft replacement).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze